hazard of 2.89 for stroke in patients presenting with seizers in late-life. 5 The risk remains unclear regarding young patients with epilepsy. We used the National Health Insurance (NHI) Research Database to evaluate the risk of stroke among adult patients with epilepsy in a 10-year follow-up period. This population-based retrospective cohort study addressed the epilepsy-cerebral stroke link, considering the associations with sex, age, the average defined daily doses (DDDs) of antiepilepsy drugs, and comorbidities.
Methods

Data source
Taiwan officially commenced the NHI program in March 1995, providing universal health insurance to 99% of the population and 92% of the medical institutions in Taiwan were included in the system. [19] [20] [21] This study used the Longitudinal Health Insurance Database, which includes historical claims data from 1996 to 2009 for 1 million people randomly sampled by the National Health Research Institute (NHRI) from the entire insured population registered in 2000. Disease diagnoses were coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) for the diagnosis of disease. The outpatient claims data consisted of 3 diagnoses, and the inpatient claims data consisted of 5 diagnoses, accompanied by detailed pharmaceutical prescriptions and treatment procedures. The NHRI scrambled patient identifications and used surrogate numbers to secure patient privacy. The present study was approved by the ethics committee at China Medical University and Hospital.
Study population
To increase the validity of the diagnoses, we selected patients newly diagnosed with epilepsy in 2000-2008 (ICD-9-CM, code 345), who were prescribed antiepileptic drugs, as the epilepsy cohort. 18 The index date of the epilepsy cohort was set as the epilepsy diagnosis date. Patients in the comparison cohort were randomly selected from individuals who were free from epilepsy in 1996-2008 and frequency matched according to sex, age (per 5 years), and all comorbidities, except for atrial fibrillation (AF) (AF was not included in the frequency criteria because of low AF prevalence in individuals without epilepsy; however, the proportion of AF in the epilepsy cohort was 2.0%, and that in the comparison cohort was 1.0%), yielding a 4-fold sample size. The index date for the comparison cohort was randomly assigned the same month and day as the index year of the matched case. The follow-up time was terminated on the date of stroke event diagnosis, withdrawal from the insurance program, or on December 31, 2009. The event of interest in the study was a subsequent new stroke event (ICD-9-CM 430-438), which was determined by brain imaging, that was identified using the inpatient file. We also distinguished the stroke events as either ischemic strokes (ICD-9-CM 433-438) or hemorrhagic strokes (ICD-9-CM 430-432), excluding stroke patients aged less than 20 years. We also calculated the average DDDs of AEDs in the epilepsy cohort as the total sum of AEDs used during the observation time divided by the total follow-up duration (DDD/year). The AEDs were phenytoin (ATC code: N03AB02), carbamazepine (ATC code: N03AF01), gabapentin (ATC code: N03AX12), levetiracetam (ATC code: N03AX14), oxcarbazepine (ATC code: N03AF02), tiagabine (ATC code: N03AG06), topiramate (ATC code: N03AX11), vigabatrin (ATC code: N03AG04), phenobarbital (ATC code: N03AA02), and valproate (ATC code: N03AG01). The epilepsy cohort was recategorized into 3 subcohorts according to the tertile cutpoint of the average DDDs.
Information on potential confounders, such as demographic factors or the comorbidity of stroke, were also collected in this study. The comorbidities used in this study were hypertension (ICD-9-CM 401-405) and hyperlipidemia (ICD-9-CM 272), both of which were diagnosed at least 3 times; diabetes mellitus (DM)(ICD-9-CM 250), diagnosed at least 2 times; coronary artery disease (CAD)(ICD-9-CM 410-413, 414.0, 414.8, and 414.9); and AF (ICD-9-CM 427.3), diagnosed once.
Statistical analysis
We used Chi-square tests to examine the categorical variables and t tests to examine the continuous variables to compare the characteristics between the epilepsy and comparison cohorts. The incidence of stroke in the 2 groups was determined. Compared with the comparison cohort, the hazard ratio (HR) and 95% confidence interval (CI) of stroke for the epilepsy cohort were estimated using the Cox proportional hazards regression model after adjusting for AF. The Kaplan-Meier method was used to evaluate the stroke-free curves of stroke for the epilepsy and comparison cohorts, and the variations in the curves were examined using logrank tests.
Statistical analysis and data management were performed using the Statistical Analysis System (SAS) 9.3 (SAS Institute Inc., Cary, NC, USA), and the survival curve was determined using R 2.13.0 (The R Foundation for Statistical Computing, Vienna, Austria). A P value less than 0.05 was considered significant.
Results
This study used 15,248 comparison individuals and 3812 patients with epilepsy, yielding a mean age of 50 years, and 41.7% of the participants were women (Table 1) . Except for AF, the distribution of all the comorbidities between the epilepsy and comparison cohorts was similar (P > .99).
The results of using the Kaplan-Meier model shown in Fig. 1 indicated that the cumulative incidence of stroke for the epilepsy cohort was significantly higher than that for the comparison cohort (logrank test < 0.0001). The incidence of stroke was approximately 3-fold higher in the epilepsy cohort than in the comparison cohort (24.08 vs. 7.96 per 1000 person-year), yielding an HR of 2.92 (95% CI = 2.58-3.30) after adjusting for AF ( Table 2 ). The incidence of ischemic stroke was nearly 3-fold higher than that of hemorrhagic stroke for both cohorts. Compared with the comparison cohort, the epilepsy cohort exhibited HRs of 2.85 (95% CI = 2.49-3.26) for ischemic stroke and 3.30 (95% CI = 2.46-4.43) for hemorrhagic stroke. Relative to the comparison cohort, the epilepsy patient who had the lowest dose of AED exposure exhibited a 1.30-fold increased risk of developing stroke (HR = 1.30, 95% CI = 1.03-1.64), and the epilepsy patient who had the highest dose of AED exposure exhibited the greatest increased risk of stroke (HR = 5.84, 95% CI = 5.02-6.80). The results also indicated that the risk of overall stroke, ischemic stroke, and hemorrhagic stroke occurrences increased as AED exposure increased (P for trend < .0001). Table 3 shows the stratification analysis for the risk of subsequent stroke and the demographic factor and comorbidity statuses of the study cohorts. The stroke risk was higher for men than for women and increased as age increased. However, the age-specific HR for the epilepsy cohort, compared with that of the comparison cohort, was highest in the young patients aged 20-39 years (HR = 8.88, 95% CI = 5.71-13.82). Regarding the patients not presenting with comorbidities, the epilepsy cohort exhibited an adjusted HR of 5.88 (95% CI = 4.58-7.56) for stroke, compared with the comparison cohort. The comorbidity-specific adjusted HR for the epilepsy cohort ranged between 1.93 and 2.66, compared with the comparison cohort.
Discussion
After adjusting for potential confounding factors, including demographic factors and the comorbidity of stroke, the results of the present study indicated that the incidence of ischemic stroke for the patients with epilepsy was significantly higher than that for the patients in the comparison cohort. The men were at a higher risk of ischemic stroke than the women were in this study. Cleary et al. determined that patients who presented with seizures after 60 years of age exhibited a substantial risk of stroke. 5 Another study determined that epilepsy may increase the risk of cardiovascular disease and stroke. 22 We also observed a sharp increase in the incidence of stroke as age increased. The incidence was 6.3-fold higher for the patients aged 60 years than for those aged 20-39 years in the epilepsy cohort. No previous comprehensive studies have compared the age-specific incidence of stroke in patients with epilepsy. Based on our research, this is the first study to document such findings by examining data that were based on a generalized population-based cohort. Cerebral stroke is a heterogeneous disease that comprises several subtypes consisting of different etiologies. 23 Traditional cardiovascular risk assessments for each sex include standard lipid measurements (e.g., total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) and assessments of nonlipid risk factors (e.g., hypertension or diabetes mellitus). These conditions interact to promote atherosclerosis formation, which is the artery-clogging process that causes heart attacks and strokes. 24, 25 Specific diseases, such as carotid stenosis, AF, and lifestyle-related factors (e.g., smoking, absence of regular exercise, and being overweight) are well-known stroke risk factors. 26 Previous studies have determined that statin could potentially prevent epilepsy. 27, 28 No increase in vascular risk factors was observed in patients with epilepsy 29 ; therefore, we attempted to control the comorbidities between the epilepsy and comparison cohorts in this study. In the data obtained in the present study, the comorbidity-specific HR of stroke risk suggested that the epilepsy cohort and control group presenting with hypertension, diabetes, CAD, and hyperlipidemia exhibited a significantly high risk of stroke. Several studies have reported that the plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, and its components increased in patients who were prescribed longterm carbamazepine (CBZ), 30, 31 phenobarbital, or VPA therapy. 32, 33 Dyslipidemia causes atherosclerosis in arterial vessels. 34 Increased body weight, which is a frequently encountered side effect associated with long-term VPA use, 35, 36 plays a modulatory role in promoting these risks of vascular injury. 37, 38 Prospective studies have established that increased carotid artery intimamedia thickness (CIMT) is involved in subsequent hypertension and dyslipidemia in adults, and that increased CIMT typically occurs in association with an increased incidence of acute cardiovascular and cerebrovascular events. 39 High CIMT values, increased plaque scores, the number of plaques, and the degree of carotid stenosis have been correlated with cerebrovascular disorder. 40 This study determined that the relationship between the risk of stroke and AEDs was dose-dependent. Fig. 1 . The Kaplan-Meier model used to measure the cumulative incidence curve for stroke in the study cohort. A marked observation in the present study was that, among the patients in both cohorts who did not present with any comorbidities, the patients in the epilepsy cohort exhibited a 3-fold increased stroke risk, compared with the patients in the comparison cohort. Regarding age, the cumulative data indicated that the young patients (20-39 years) in the epilepsy cohort exhibited a significantly increased stroke risk, compared with the patients in the comparison cohort who were in the same age range. This is a striking finding. The possible reason is the early onset of epilepsy and treatment resistance. We hypothesized that the harmful effects of recurrent epilepsy and vascular risk factors contribute to the overproduction of reactive oxygen species and the oxidation of low-density lipoproteins into atherogenic particles, which play a pivotal role in the pathogenesis of atherosclerosis. 41, 42 In addition, Hamed et al. provided evidence suggesting that CIMT may increase and various vascular risk factors may worsen in patients with chronic epilepsy and/or are provided treatment with antiepileptic medications. 43 In addition, long-term AED therapy may cause low-grade systemic inflammation and increased oxidative stress, which is manifested by a substantially increased CIMT 7, 44 and high concentrations of highsensitivity C-reactive protein, which are recognized as activators of the extrinsic pathway of the coagulation system. 40, 45 A positive relationship has been observed between the duration of CBZ, PHT, or VPA monotherapy and the acceleration of atherosclerosis in the CIMT of patients with epilepsy, albeit by using different underlying mechanisms. 46 Young epilepsy patients might have been suffering from seizure attacks since childhood and also might have undergone long-term AED therapy, which contribute to the risk of stroke. This population-based study used a large random sample of insured patients and provided a source for exploring the epidemiologic characteristics of cerebral stroke in patients with epilepsy. Nevertheless, the present study presented several limitations. First, the diagnosis of stroke might be overestimated among the epilepsy cohort because mimic stroke may have occurred among the patients with epilepsy, 47, 48 and no brain images were available to illustrate the unequivocal evidence of a stroke in the database. The evaluation process for identifying seizures and strokes might include brain images taken by physicians to evaluate the possible etiology. Although image data were unavailable in the claims data that we obtained, we attempted to evaluate the incidence of stroke by referring to the inpatient database, which used a more careful survey for evaluating the diagnoses to prevent possible overestimation. Second, we could not estimate the precise temporal relationships between epilepsy and subsequent stroke occurrence because the index date for the diagnosis of epilepsy might not have been the onset date of the disease. This is because the diagnosis of epilepsy was based on the date registered in the claims data after the patients visited a physician, and because of a possible delay in the diagnosis of epilepsy from the time of initial symptoms. 27 Thus, the onset of epilepsy might not be based on the date of diagnosis. We attempted to estimate the incidence of stroke after the diagnosis of epilepsy. Finally, the information on several cardiovascular risk factors, including smoking, body mass index, the actuarial concentrations of lipid profiles, blood glucose levels, blood pressure, the CIMT, education level, and occupation were also unavailable in the database. Furthermore, the DDD provides information on only the prescriptions received by patients; medication adherence and effect information was not available.
Conclusion
The patients with epilepsy exhibited an increased risk of cerebral stroke even after controlling the comorbidities of stroke risk factors, compared with the patients in the general population. This finding indicates the key epidemiological concerns and risk factors that are involved in the development of stroke in patients with epilepsy. This finding may have implications for the development of prevention strategies that can be employed when treating patients with epilepsy, particularly for high-risk individuals.
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